Diabetic Macular Edema
📧 Sign up to get email alerts when something new happens for Diabetic Macular Edema.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-04-24EMA Authorised: Ranluspec (ranibizumab) — Lupin Europe GmbH
EMA authorised Ranluspec (ranibizumab) from Lupin Europe GmbH. The product is indicated for several retinal conditions including wet age-rel…
-
EMA approval · 2026-04-14EMA Authorised: Pavblu (aflibercept) — Amgen Technology (Ireland) UC
EMA has authorised Pavblu (aflibercept) by Amgen Technology (Ireland) UC for multiple ocular indications including wet age-related macular d…
-
EMA approval · 2026-04-10EMA Authorised: Mynzepli (aflibercept) — Advanz Pharma Limited
The European Union has authorised Mynzepli (aflibercept) from Advanz Pharma Limited for multiple retinal diseases, including wet age-related…
-
FDA approval · 2026-04-02FDA Approved: EYLEA HD — Supplemental Application (Regeneron Pharmaceuticals, Inc)
FDA approved a supplemental application for EYLEA HD, a high-dose formulation of aflibercept, expanding the product's labeling.
-
FDA approval · 2026-03-11FDA Approved: OZURDEX — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for OZURDEX (dexamethasone intravitreal implant) submitted by Allergan, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-04EMA Authorised: Eylea (aflibercept) — Bayer AG
The EMA authorised Eylea (aflibercept) from Bayer AG for multiple ocular indications, including wet age-related macular degeneration, macula…
-
EMA approval · 2026-03-03EMA Authorised: Afqlir (aflibercept) — Sandoz GmbH
The EMA authorised Afqlir (aflibercept) from Sandoz GmbH for retinal conditions including wet age-related macular degeneration, macular edem…
-
EMA approval · 2026-01-19EMA Authorised: Opuviz (aflibercept) — Samsung Bioepis NL B.V.
EMA authorised Opuviz (aflibercept) by Samsung Bioepis NL B.V. for treating several retinal conditions including wet age-related macular deg…
-
EMA approval · 2026-01-09EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.
EMA authorised Rimmyrah (ranibizumab) for several ocular indications including wet age-related macular degeneration and macular edema; decis…
-
EMA approval · 2026-01-06EMA Authorised: Vabysmo (Faricimab) — Roche Registration GmbH
The EMA authorised Vabysmo (faricimab) by Roche Registration GmbH for treatment of wet age-related macular degeneration, macular edema, and …
-
EMA approval · 2025-12-10EMA Authorised: Eydenzelt (aflibercept) — Celltrion Healthcare Hungary Kft.
EMA authorised Eydenzelt (aflibercept) from Celltrion Healthcare Hungary Kft. for multiple ocular conditions including wet age-related macul…
-
EMA approval · 2025-11-21EMA Authorised: Eiyzey (aflibercept) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
The EMA authorised Eiyzey (aflibercept) from Zaklady Farmaceutyczne Polpharma S.A. for multiple retinal diseases, including wet age-related …
-
FDA approval · 2025-11-19FDA Approved: EYLEA HD — Supplemental Application (Regeneron Pharmaceuticals, Inc)
The FDA approved a supplemental application for EYLEA HD (aflibercept) by Regeneron, introducing a high-dose formulation.
-
EMA approval · 2025-11-14EMA Authorised: Epruvy (previously Ranibizumab Midas) (ranibizumab) — Midas Pharma GmbH
Epruvy, a new marketed form of ranibizumab by Midas Pharma, has been authorised for treating wet age-related macular degeneration, macular e…
-
EMA approval · 2025-11-14EMA Authorised: Ranivisio (ranibizumab) — Midas Pharma GmbH
The EMA authorised Ranivisio (ranibizumab) for ocular indications including wet age-related macular degeneration, macular edema, and diabeti…
-
EMA approval · 2025-11-13EMA Authorised: Afiveg (aflibercept) — STADA Arzneimittel AG
The EMA has authorised Afiveg, an aflibercept product by STADA, for multiple retinal conditions including wet age-related macular degenerati…
-
FDA approval · 2025-11-12FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
The FDA approved a supplemental Biologics License Application for BYOOVIZ (ranibizumab-nuna) from Biogen, expanding regulatory clearance for…
-
EMA approval · 2025-11-12EMA Authorised: Eyluxvi (aflibercept) — Biolitec pharma Limited Zweigniederlassung Jena
EMA authorised Eyluxvi (aflibercept) from Biolitec pharma Limited Zweigniederlassung Jena for treatment of wet age-related macular degenerat…
-
EMA approval · 2025-11-07EMA Authorised: Baiama (aflibercept) — Formycon AG
EMA authorised Baiama, a biosimilar aflibercept from Formycon AG, for multiple retinal diseases including wet age-related macular degenerati…
-
EMA approval · 2025-11-07EMA Authorised: Ahzantive (aflibercept) — Formycon AG
EMA authorised Ahzantive (aflibercept) from Formycon AG for several retinal diseases including wet age-related macular degeneration and diab…
-
EMA approval · 2025-11-04EMA Authorised: Vgenfli (aflibercept) — Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.
The EMA authorized Vgenfli (aflibercept) from Polpharma for multiple retinal diseases, including wet age-related macular degeneration, macul…
-
FDA approval · 2025-08-15FDA Approved: BYOOVIZ — Supplemental Application (BIOGEN INC.)
FDA approved a supplemental application for BYOOVIZ (ranibizumab-nuna) from Biogen, updating its labeling with additional indications for oc…
-
FDA approval · 2025-03-12FDA Approved: ILUVIEN — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for ILUVIEN (fluocinolone acetonide intravitreal implant) by ANI Pharmaceuticals, Inc.
-
FDA approval · 2024-10-10FDA Approved: EYLEA HD — Supplemental Application (Regeneron Pharmaceuticals, Inc)
The FDA approved a supplemental application for EYLEA HD (aflibercept) from Regeneron, enabling use of the high-dose formulation for treatin…
-
FDA approval · 2024-07-03FDA Approved: VABYSMO — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for VABYSMO (faricimab) submitted by Genentech, Inc., indicating an update to the product labeling o…